Analyst Rating Update on Gilead Sciences (GILD)

Gilead Sciences (GILD) : Zacks Investment Research ranks Gilead Sciences (GILD) as 4, which is a Sell recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 9 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 18 research analysts is 2.06, which indicates as a Buy.

Gilead Sciences (GILD) : 13 Wall Street analysts covering Gilead Sciences (GILD) believe that the average level the stock could reach for the short term is $111.31. The maximum price target given is $133 and the minimum target for short term is around $93, hence the standard deviation is calculated at $11.23.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Argus Research downgrades its rating on Gilead Sciences (NASDAQ:GILD). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on July 29, 2016.


Gilead Sciences (NASDAQ:GILD): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $79.72 and $79.11 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.17. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.09, notching a gain of 0.65% for the day. The total traded volume was 10,867,558 . The stock had closed at $79.57 on the previous day.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.